secwatch.observer — SEC 8-K summary
======================================

Issuer:     NRX Pharmaceuticals, Inc. (NRXP)
CIK:        0001719406
Form:       8-K
Filed at:   2026-08-07T11:00:32+00:00
Accession:  0001437749-26-026428
Event type: regulatory
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01
LLM model:  deepseek-v4-flash:cloud@v2

NRx Pharmaceuticals FDA ANDA review: no drug deficiencies; packaging issue to resolve
--------------------------------------------------------------------------------

- FDA first-round ANDA review for preservative-free ketamine found no major drug-component deficiencies (July 30, 2026).
- One major deficiency: twist-off cap on luer lock vial; FDA wants confirmation no patient-safety risk from tip deformation.
- Company cited 11.9M doses shipped across 3 approved ANDA products with same vial; 3,500 vials from 7 batches tested with no defects.
- Aug 6 clarification meeting with FDA Office of Generic Drugs; FDA requested manufacturer certifications on same lines/machinery, committed to shortest review cycle.
- FDA recognizes ketamine as strategic drug on shortage list; management optimistic for first commercial sales in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1719406/000143774926026428/0001437749-26-026428-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1719406/000143774926026428/nrxp20260806_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-026428

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer